Korea M&A Corporation

A day after Verizon Wireless surprised everyone by quickly scooping up Alltel ( NYSE: AT) for $28.1 billion, reactions are mixed on what it will mean for Alltel customers, what it means for Verizon's debt load going forward, how government regulators will react, and how it will affect the rest of the industry. Here's a round-up of the thoughts and opinions: -- Verizon Emphasizes Wireless: UBS an..

Source from http://news.yahoo.com/s/afp/20080603/bs_afp/chinatelecommergerunicomnetcom Wireless telecom provider China Unicom will take over fixed-line operator China Netcom in a share swap valued at 56 billion dollars, Unicom officials have said. The combined firm will be an integrated company with a full range of product offerings, including mobile and fixed-line phone services, and broadband ..

China Merchants Bank has agreed in principle to buy control of Hong Kong's Wing Lung Bank in a deal that would value the lender at over $4.5 billion, a person familiar with the situation said on Friday. The person, who could not be identified given the sensitivity of the situation, said no deal had been signed and negotiations were ongoing. Shares in both lenders were suspended on Friday pending..

Source from http://online.wsj.com/article/SB121199901949126765.html?mod=googlenews_wsj Closely held Japanese drug, food and drink maker Otsuka Pharmaceutical Co. said Wednesday it will pay about $1.2 billion to buy a 49% stake in Alma SA, the maker of Cristaline, France's biggest-selling still-water brand by volume. The move by Tokyo-based Otsuka -- buying part of a stake formerly held by Groupe..

Rohm Co. Ltd. has kept a relatively low profile, as compared to other chip makers in Japan, such as NEC, Sony and Toshiba. Now, Rohm wants to share the limelight. Rohm confirmed that it has acquired the semiconductor operations of Japan's Oki Electric Industry Co. Ltd. Rohm is also making other headlines by moving into the organic electroluminescence (OLED) market. Formed in 1958, Rohm (Kyoto) s..

Alnylam Pharmaceuticals (ALNY - Cramer's Take - Stockpickr) and Japan's Takeda Pharmaceutical have teamed up to develop RNAi therapeutics for treatments for cancer and metabolic disease. RNAi therapeutics target the cause of diseases by silencing specific messenger RNAs (mRNAs) to prevent disease-causing proteins from being made. According to the five-year agreement, Takeda gets access to Alnyla..